Mereo BioPharma Group PLC (MREO) Enterprise Value to EBITDA Ratio

Public company logo of Mereo BioPharma Group plc (MREO)

Mereo BioPharma (MREO) operates as a biopharmaceutical business, integrating environmental standards through filtration upgrades and laboratory energy efficiency. Mereo BioPharma (MREO) relies on third-party logistics operators for the delivery of orphan drugs, ensuring supply reliability through strict agreements. This chart demonstrates an EV/EBITDA of 0.00, complemented by the implementation of AI monitoring in clinical trials to automate patient data processing.

Mereo BioPharma Group plc - MREO Company Value to EBITDA (period 11/23/2025 - 11/10/2026)

Comprehensive metric breakdowns and analytics for mereobiopharma.com (MREO)

- current price and projected stock value:
Stock Price Mereo BioPharma Group plc|MREO - Analyst Median Target
- market capitalization details:
Market Valuation Mereo BioPharma Group plc|MREO - Full Business Value
- business book valuation details:
Book Value per Share Mereo BioPharma|MREO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio mereobiopharma.com|MREO - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Mereo BioPharma|MREO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Mereo BioPharma Group plc|MREO - Company Aggregate Indebtedness|Debts to Book Capitalization Mereo BioPharma Group plc|MREO - Company Long-Term Loans and Borrowings|Company Short-Term Debts Mereo BioPharma|Quick Liquidity mereobiopharma.com
- financial results and valuation multiples details:
MREO - Final Profit|Expected Profit Mereo BioPharma|MREO - Price to Earnings Ratio|Forward P/E Multiple Mereo BioPharma Group plc|MREO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mereo BioPharma Group plc|MREO - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Mereo BioPharma|MREO - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months mereobiopharma.com|MREO - Earnings per share increase in current year|Earnings growth forecast for next year Mereo BioPharma
Fundamental valuation:Mereo BioPharma Group PLC MREO
Manufactured products of Mereo BioPharma Group plc

Portfolio managers are analyzing the operating model of Mereo BioPharma (MREO) through the lens of its ability to generate cash flow. This indicator compares the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization, thereby determining the payback period of the assets. The trend in the company's EV/EBITDA ratio allows analysts to filter out speculative noise from the real valuation of setrusumab's development. The stability of this multiple confirms the issuer's resilient position in executing orphan drug strategies.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|protalix.com (PLX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pliant Therapeutics Inc|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rein Therapeutics, Inc. (RNTX)|Enterprise Value to EBITDA Ratio gelteq.com GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Polyrizon Ltd (PLRZ) - Enterprise Value to EBITDA Ratio|AEZS: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics, Inc (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|RPHM: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CSCI